-

NeuroPace to Participate in Upcoming Healthcare Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in September.

  • NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2025 Healthcare Conference, on Wednesday, September 3 in Boston, MA.
  • NeuroPace management will participate in a fireside chat discussion at the Cantor Global Healthcare Conference on Thursday, September 4 at 9:45am ET, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Contacts

Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
investors@neuropace.com

NeuroPace, Inc.

NASDAQ:NPCE

Release Versions

Contacts

Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
investors@neuropace.com

More News From NeuroPace, Inc.

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. First Quarter 2026 Highlights Total revenue of $22.1 million in the quarter. Excluding DIXI Medical, total revenue of $22.0 million representing 20.1% year over year growth RNS System revenue of $21.7 million in the quarter, r...

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close on Tuesday, May 12, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing...

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meet...
Back to Newsroom